Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.

Abstract: A polyamide coating slurry and its preparing method, and a process for preparing polyamide-coated fabric for printing are provided. The present disclosure provides a polyamide coating slurry for precise inkjet printing with wide applicability simple preparation steps. The surface structure and lipophilicity of the coating can be changed by mixing polyvinyl butyral and polyoxypropylene lauryl ether, urea and poly-N-isopropylacrylamide in polyamide 6, so that the adsorption properties and permeability of the coating to ink are greatly improved, and thus high-precision inkjet printing can be realized.

Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I. or a co-crystal, solvate, salt or combination thereof.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: One embodiment provides a method and system for joint payment. During operation, a joint-payment server receives a joint-payment request comprising an identifier of a user initiating a joint payment and an identifier of a user to-be-included in the joint payment; determines, based the identifiers of the user initiating the joint payment and the to-be-included user, whether a binding relationship has been established between the user initiating the joint payment and the to-be-included user; in response to determining that the binding relationship has been established, generates graphic codes respectively corresponding to the user initiating the joint payment and the to-be-included user; and sends the graphic codes to a terminal device associated with the user initiating the joint payment, thereby facilitating the terminal device to display the graphic codes to complete the joint payment.

Abstract: Provided are methods of preparing compounds and pharmaceutical compositions for treating Filoviridae virus infections The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

Abstract: Provided are methods of preparing compounds and pharmaceutical compositions comprising a compound Formula VIII for treating Filoviridae virus infections. In one aspect, the compound of Formula VIII is formed from a reaction mixture comprising the compound of Formula IX, the compound of Formula X, a coupling agent such as magnesium chloride and a non-nucleophilic base such as diisopropylethylamine. The compound of Formula IX can be formed from a compound of Formula V and a cyanating agent. The compound of Formula V can be synthesized from a reaction mixture comprising a deprotonating agent such as phenylmagnesium chloride; a silylating agent such as chlorotrimethylsilane; a coupling agent such as isopropylmagnesium chloride, an additive such as LaCl3-2LiCl, LaCl3, CeCl3, NdCl3, or YCl3; a compound of Formula VI; and 7-iodopyrrolo[2,1-f][1,2,4]triazin-4-amine. The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I. or a co-crystal, solvate, salt or combination thereof.

Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.

Abstract: A scroll compressor that includes a housing and scroll compressor bodies disposed in the housing. A motor is disposed within the housing and operably connected to a drive shaft for driving one of the scroll compressor bodies. The drive shaft is rotationally supported at one end by a crankcase which includes a bearing housing and a bearing. The crankcase includes a plurality of openings or gas passages passing through the crankcase, as well as a plurality of generally cylindrical sections positioned respectively between adjacent openings. The cylindrical sections define contact regions which can engage an inner periphery of the housing when the crankcase is mounted therein.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: One embodiment provides a method and system for joint payment. During operation, a joint-payment server receives a joint-payment request comprising an identifier of a user initiating a joint payment and an identifier of a user to-be-included in the joint payment; determines, based the identifiers of the user initiating the joint payment and the to-be-included user, whether a binding relationship has been established between the user initiating the joint payment and the to-be-included user; in response to determining that the binding relationship has been established, generates graphic codes respectively corresponding to the user initiating the joint payment and the to-be-included user; and sends the graphic codes to a terminal device associated with the user initiating the joint payment, thereby facilitating the terminal device to display the graphic codes to complete the joint payment.

Abstract: The present disclosure provides methods for preparing (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol or a salt thereof and related key intermediates.

Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.

Abstract: Provided are methods of preparing compounds and pharmaceutical compositions for treating Filoviridae virus infections The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.